1-deoxymannojirimycin profile

1-Deoxymannojirimycin (DMJ) is a naturally occurring iminosugar that acts as a potent inhibitor of α-mannosidase enzymes. It has been studied extensively for its potential therapeutic applications in various diseases. DMJ inhibits the processing of glycoproteins by blocking the removal of mannose residues from N-linked glycans. This disruption of glycosylation can have significant effects on cellular function, leading to potential therapeutic benefits in various conditions.

DMJ is a potent inhibitor of α-mannosidase enzymes, with a Ki value of 0.1 μM for human α-mannosidase II. This potent inhibition makes it a useful tool for studying the role of glycosylation in various biological processes.

DMJ has been shown to have a variety of biological effects, including inhibition of viral entry, modulation of immune responses, and reduction of inflammation. It has been investigated for its potential therapeutic uses in diseases such as cancer, HIV infection, and Alzheimer's disease.

DMJ has been synthesized by various methods, including chemical synthesis and enzymatic methods. Chemical synthesis typically involves the use of protecting groups and multi-step reactions, while enzymatic synthesis relies on the use of specific enzymes to catalyze the conversion of readily available starting materials.

Research into DMJ is driven by its potential therapeutic applications in various diseases. Its ability to modulate glycosylation pathways makes it an attractive target for the development of novel drugs that can target specific biological processes. Further studies are ongoing to evaluate the efficacy and safety of DMJ in clinical settings.'

ID Source	ID
PubMed CID	72258
CHEMBL ID	84844
SCHEMBL ID	329674
MeSH ID	M0026525

Synonym
CHEMBL84844 ,
(2r,3r,4r,5r)-2-(hydroxymethyl)-3,4,5-piperidinetriol
BIO1_001458
BIO1_000480
BIO1_000969
BSPBIO_000991
(2r,3r,4r,5r)-2-(hydroxymethyl)piperidine-3,4,5-triol
d-deoxymannojirimycin
3,4,5-piperidinetriol, 2-(hydroxymethyl)-, (2r,3r,4r,5r)-
ox5 ,
1-deoxymannojirimycin
nsc625109
deoxymannojirimycin
DMJ ,
84444-90-6
1FO2
DB03955
d-manno-deoxynojirimycin
1HXK ,
2-hydroxymethyl-piperidine-3,4,5-triol
NCGC00025086-02
SMP2_000289
NCGC00025086-03
HMS1990A13
HMS1792A13
bdbm50065259
(2r,3r,4r,5r)-2-(hydroxymethyl)piperidine-3,4,5-triol, 11
(2r,3r,4r,5r)-2-hydroxymethyl-piperidine-3,4,5-triol
AKOS006238598
lu 1
SCHEMBL329674
84444-90-6-deleted name
Q27094814
NCGC00015383-05

Protein Targets (36)

Potency Measurements

Protein	Taxonomy	Measurement	Average (µ)	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
lysosomal alpha-glucosidase preproprotein	Homo sapiens (human)	Potency	28.1838	0.0366	19.6376	50.1187	AID2112; AID2113
thyroid hormone receptor beta isoform a	Homo sapiens (human)	Potency	1.7783	0.0100	39.5371	1,122.0200	AID1479
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Chain A, ALPHA1,2-MANNOSIDASE	Homo sapiens (human)	IC50 (µMol)	20.0000	0.2000	10.1000	20.0000	AID977608
Chain A, ALPHA1,2-MANNOSIDASE	Homo sapiens (human)	IC50 (µMol)	20.0000	0.2000	10.1000	20.0000	AID977608
Chain A, Alpha-mannosidase Ii	Drosophila melanogaster (fruit fly)	IC50 (µMol)	400.0000	0.0200	200.0100	400.0000	AID977608
Chain A, ALPHA-MANNOSIDASE II	Drosophila melanogaster (fruit fly)	IC50 (µMol)	400.0000	0.0200	200.0100	400.0000	AID977608
Chain A, Alpha-mannosidase Ii	Drosophila melanogaster (fruit fly)	IC50 (µMol)	400.0000	0.0200	200.0100	400.0000	AID977608
Tissue alpha-L-fucosidase	Homo sapiens (human)	IC50 (µMol)	221.0000	0.1400	0.2350	0.4100	AID240839
Tissue alpha-L-fucosidase	Homo sapiens (human)	Ki	4.7000	0.0100	1.5967	4.7000	AID36836
Sucrase-isomaltase, intestinal	Rattus norvegicus (Norway rat)	IC50 (µMol)	110.0000	0.0400	1.8483	10.0000	AID240843
Tissue alpha-L-fucosidase	Bos taurus (cattle)	IC50 (µMol)	39.0000	0.0050	0.0575	0.1100	AID241392
Tissue alpha-L-fucosidase	Bos taurus (cattle)	Ki	4.7000	0.0017	1.1769	4.7000	AID238243
Alpha-1,2-mannosidase family protein	Bacteroides thetaiotaomicron VPI-5482	Ki	12,500.0000	5.0000	5.0000	5.0000	AID514924; AID514932
Putative alpha-1,2-mannosidase	Bacteroides thetaiotaomicron VPI-5482	Ki	12,500.0000	5.0000	5.0000	5.0000	AID514924; AID514932
Alpha-1,2-mannosidase, putative	Bacteroides thetaiotaomicron VPI-5482	Ki	12,500.0000	5.0000	5.0000	5.0000	AID514924; AID514932
Putative alpha-1,2-mannosidase	Bacteroides thetaiotaomicron VPI-5482	Ki	12,500.0000	5.0000	5.0000	5.0000	AID514924; AID514932
Putative alpha-1,2-mannosidase	Bacteroides thetaiotaomicron VPI-5482	Ki	12,500.0000	5.0000	5.0000	5.0000	AID514924; AID514932
Putative alpha-1,2-mannosidase	Bacteroides thetaiotaomicron VPI-5482	Ki	12,500.0000	5.0000	5.0000	5.0000	AID514924; AID514932
Putative alpha-1,2-mannosidase	Bacteroides thetaiotaomicron VPI-5482	Ki	12,500.0000	5.0000	5.0000	5.0000	AID514924; AID514932
Glycoside hydrolase family 92	Bacteroides thetaiotaomicron VPI-5482	Ki	12,500.0000	5.0000	5.0000	5.0000	AID514924; AID514932
Glycoside hydrolase family 92	Bacteroides thetaiotaomicron VPI-5482	Ki	12,500.0000	5.0000	5.0000	5.0000	AID514924; AID514932
Alpha-1,2-mannosidase	Bacteroides thetaiotaomicron VPI-5482	Ki	12,500.0000	5.0000	5.0000	5.0000	AID514924; AID514932
Putative alpha-1,2-mannosidase	Bacteroides thetaiotaomicron VPI-5482	Ki	12,500.0000	5.0000	5.0000	5.0000	AID514924; AID514932
Alpha-1,2-mannosidase, putative	Bacteroides thetaiotaomicron VPI-5482	Ki	12,500.0000	5.0000	5.0000	5.0000	AID514924; AID514932
Putative alpha-1,2-mannosidase	Bacteroides thetaiotaomicron VPI-5482	Ki	12,500.0000	5.0000	5.0000	5.0000	AID514924; AID514932
Alpha-1,2-mannosidase	Bacteroides thetaiotaomicron VPI-5482	Ki	12,500.0000	5.0000	5.0000	5.0000	AID514924; AID514932
Alpha-1,2-mannosidase, putative	Bacteroides thetaiotaomicron VPI-5482	Ki	12,500.0000	5.0000	5.0000	5.0000	AID514924; AID514932
Putative alpha-1,2-mannosidase	Bacteroides thetaiotaomicron VPI-5482	Ki	12,500.0000	5.0000	5.0000	5.0000	AID514924; AID514932
Putative alpha-1,2-mannosidase	Bacteroides thetaiotaomicron VPI-5482	Ki	12,500.0000	5.0000	5.0000	5.0000	AID514924; AID514932
Alpha-1,2-mannosidase	Bacteroides thetaiotaomicron VPI-5482	Ki	12,500.0000	5.0000	5.0000	5.0000	AID514924; AID514932
Putative alpha-1,2-mannosidase	Bacteroides thetaiotaomicron VPI-5482	Ki	12,500.0000	5.0000	5.0000	5.0000	AID514924; AID514932
Putative alpha-1,2-mannosidase	Bacteroides thetaiotaomicron VPI-5482	Ki	12,500.0000	5.0000	5.0000	5.0000	AID514924; AID514932
Putative alpha-1,2-mannosidase	Bacteroides thetaiotaomicron VPI-5482	Ki	12,500.0000	5.0000	5.0000	5.0000	AID514924; AID514932
Putative alpha-1,2-mannosidase	Bacteroides thetaiotaomicron VPI-5482	Ki	12,500.0000	5.0000	5.0000	5.0000	AID514924; AID514932
Alpha-1,2-mannosidase family protein	Bacteroides thetaiotaomicron VPI-5482	Ki	12,500.0000	5.0000	5.0000	5.0000	AID514924; AID514932
alpha-1,2-Mannosidase	Glycine max (soybean)	IC50 (µMol)	840.0000	0.4000	0.4000	0.4000	AID241119
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (25)

Process	via Protein(s)	Taxonomy
fucose metabolic process	Tissue alpha-L-fucosidase	Homo sapiens (human)
glycosaminoglycan catabolic process	Tissue alpha-L-fucosidase	Homo sapiens (human)
glycoside catabolic process	Tissue alpha-L-fucosidase	Homo sapiens (human)
glycolipid catabolic process	Tissue alpha-L-fucosidase	Homo sapiens (human)
glycolipid catabolic process	Tissue alpha-L-fucosidase	Bos taurus (cattle)
response to oxidative stress	Cyclooxygenase-2	Canis lupus familiaris (dog)
embryo implantation	Cyclooxygenase-2	Canis lupus familiaris (dog)
regulation of blood pressure	Cyclooxygenase-2	Canis lupus familiaris (dog)
response to nematode	Cyclooxygenase-2	Canis lupus familiaris (dog)
positive regulation of prostaglandin biosynthetic process	Cyclooxygenase-2	Canis lupus familiaris (dog)
positive regulation of fever generation	Cyclooxygenase-2	Canis lupus familiaris (dog)
prostaglandin secretion	Cyclooxygenase-2	Canis lupus familiaris (dog)
positive regulation of peptidyl-serine phosphorylation	Cyclooxygenase-2	Canis lupus familiaris (dog)
regulation of cell population proliferation	Cyclooxygenase-2	Canis lupus familiaris (dog)
negative regulation of apoptotic process	Cyclooxygenase-2	Canis lupus familiaris (dog)
decidualization	Cyclooxygenase-2	Canis lupus familiaris (dog)
brown fat cell differentiation	Cyclooxygenase-2	Canis lupus familiaris (dog)
cellular response to hypoxia	Cyclooxygenase-2	Canis lupus familiaris (dog)
cellular response to non-ionic osmotic stress	Cyclooxygenase-2	Canis lupus familiaris (dog)
cellular response to fluid shear stress	Cyclooxygenase-2	Canis lupus familiaris (dog)
positive regulation of brown fat cell differentiation	Cyclooxygenase-2	Canis lupus familiaris (dog)
cellular oxidant detoxification	Cyclooxygenase-2	Canis lupus familiaris (dog)
regulation of neuroinflammatory response	Cyclooxygenase-2	Canis lupus familiaris (dog)
negative regulation of intrinsic apoptotic signaling pathway in response to osmotic stress	Cyclooxygenase-2	Canis lupus familiaris (dog)
mannose metabolic process	Epididymis-specific alpha-mannosidase	Homo sapiens (human)
oligosaccharide catabolic process	Epididymis-specific alpha-mannosidase	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (9)

Process	via Protein(s)	Taxonomy
alpha-L-fucosidase activity	Tissue alpha-L-fucosidase	Homo sapiens (human)
protein binding	Tissue alpha-L-fucosidase	Homo sapiens (human)
alpha-L-fucosidase activity	Tissue alpha-L-fucosidase	Bos taurus (cattle)
peroxidase activity	Cyclooxygenase-2	Canis lupus familiaris (dog)
enzyme binding	Cyclooxygenase-2	Canis lupus familiaris (dog)
heme binding	Cyclooxygenase-2	Canis lupus familiaris (dog)
protein homodimerization activity	Cyclooxygenase-2	Canis lupus familiaris (dog)
metal ion binding	Cyclooxygenase-2	Canis lupus familiaris (dog)
protein binding	Epididymis-specific alpha-mannosidase	Homo sapiens (human)
carbohydrate binding	Epididymis-specific alpha-mannosidase	Homo sapiens (human)
metal ion binding	Epididymis-specific alpha-mannosidase	Homo sapiens (human)
alpha-mannosidase activity	Epididymis-specific alpha-mannosidase	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (10)

Process	via Protein(s)	Taxonomy
extracellular region	Tissue alpha-L-fucosidase	Homo sapiens (human)
cytoplasm	Tissue alpha-L-fucosidase	Homo sapiens (human)
azurophil granule lumen	Tissue alpha-L-fucosidase	Homo sapiens (human)
lysosomal lumen	Tissue alpha-L-fucosidase	Homo sapiens (human)
intracellular membrane-bounded organelle	Tissue alpha-L-fucosidase	Homo sapiens (human)
extracellular exosome	Tissue alpha-L-fucosidase	Homo sapiens (human)
lysosome	Tissue alpha-L-fucosidase	Homo sapiens (human)
nuclear inner membrane	Cyclooxygenase-2	Canis lupus familiaris (dog)
nuclear outer membrane	Cyclooxygenase-2	Canis lupus familiaris (dog)
cytoplasm	Cyclooxygenase-2	Canis lupus familiaris (dog)
endoplasmic reticulum membrane	Cyclooxygenase-2	Canis lupus familiaris (dog)
lysosomal lumen	Epididymis-specific alpha-mannosidase	Homo sapiens (human)
extracellular exosome	Epididymis-specific alpha-mannosidase	Homo sapiens (human)
lysosome	Epididymis-specific alpha-mannosidase	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (41)

Assay ID	Title	Year	Journal	Article
AID977608	Experimentally measured binding affinity data (IC50) for protein-ligand complexes derived from PDB	2000	The Journal of biological chemistry, Dec-29, Volume: 275, Issue:52	Structural basis for catalysis and inhibition of N-glycan processing class I alpha 1,2-mannosidases.
AID1508629	Cell Viability qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome	2021	Cell reports, 04-27, Volume: 35, Issue:4	A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1508627	Counterscreen qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: GLuc-NoTag assay	2021	Cell reports, 04-27, Volume: 35, Issue:4	A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1508628	Confirmatory qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay	2021	Cell reports, 04-27, Volume: 35, Issue:4	A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID243650	Percent inhibition of human alpha-glucosidase at 1000 uM	2005	Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6	Biological properties of D- and L-1-deoxyazasugars.
AID648439	Inhibition of JAK1-mediated GATA3 phosphorylation in PMA-stimulated human PBMC at 90 uM after 30 mins by Western blot analysis	2012	Bioorganic & medicinal chemistry letters, Jan-01, Volume: 22, Issue:1	An iminosugar N-pentafluorobenzyl-1-deoxynojirimycin as a novel potential immunosuppressant for the treatment of Th2-related diseases.
AID243726	Percent inhibition of beta-galactosidase of bovine liver at 1000 uM	2005	Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6	Biological properties of D- and L-1-deoxyazasugars.
AID240843	Inhibitory concentration against rat intestinal maltase	2005	Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6	Biological properties of D- and L-1-deoxyazasugars.
AID648435	Inhibition of Con-A-induced phospho-STAT6 expression in human PBMC at 90 uM after 72 hrs by flow cytometry (Rvb = 10.52+/-1.9%)	2012	Bioorganic & medicinal chemistry letters, Jan-01, Volume: 22, Issue:1	An iminosugar N-pentafluorobenzyl-1-deoxynojirimycin as a novel potential immunosuppressant for the treatment of Th2-related diseases.
AID243639	Percent inhibition of human beta-glucosidase at 1000 uM	2005	Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6	Biological properties of D- and L-1-deoxyazasugars.
AID243694	Percent inhibition of beta-glucosidase of almond tree at 1000 uM	2005	Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6	Biological properties of D- and L-1-deoxyazasugars.
AID243665	Percent inhibition of human alpha-galactosidase at 1000 uM	2005	Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6	Biological properties of D- and L-1-deoxyazasugars.
AID36836	Inhibitory activity measured against alpha-L-fucosidase of bovine epididymis by colorimetric assay using the D-glucose oxidase-peroxidase method	1998	Journal of medicinal chemistry, Jul-02, Volume: 41, Issue:14	Homonojirimycin isomers and N-alkylated homonojirimycins: structural and conformational basis of inhibition of glycosidases.
AID241392	Inhibitory concentration against alpha-L-fucosidase of bovine epididymis	2005	Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6	Biological properties of D- and L-1-deoxyazasugars.
AID243664	Percent inhibition of alpha-glucosidase of rice 1000 uM	2005	Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6	Biological properties of D- and L-1-deoxyazasugars.
AID240839	Inhibitory concentration against human alpha-fucosidase	2005	Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6	Biological properties of D- and L-1-deoxyazasugars.
AID648433	Immunosuppressant activity in human CD4+ T cells assessed as Con A-induced intracellular IL4 level at 90 uM after 72 hrs by flow cytometry (Rvb = 4.2+/-0.9%)	2012	Bioorganic & medicinal chemistry letters, Jan-01, Volume: 22, Issue:1	An iminosugar N-pentafluorobenzyl-1-deoxynojirimycin as a novel potential immunosuppressant for the treatment of Th2-related diseases.
AID648437	Inhibition of Con A-induced phospho-GATA3 expression in human PBMC at 90 uM after 72 hrs by flow cytometry	2012	Bioorganic & medicinal chemistry letters, Jan-01, Volume: 22, Issue:1	An iminosugar N-pentafluorobenzyl-1-deoxynojirimycin as a novel potential immunosuppressant for the treatment of Th2-related diseases.
AID243727	Percent inhibition of beta-mannosidase of rat epididymis at 1000 uM	2005	Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6	Biological properties of D- and L-1-deoxyazasugars.
AID335085	Inhibition of jack beans alpha-mannosidase	1993	Journal of natural products, Aug, Volume: 56, Issue:8	2-Hydroxymethyl-3,4-dihydroxy-6-methyl-pyrrolidine (6-deoxy-DMDP), an alkaloid beta-mannosidase inhibitor from seeds of Angylocalyx pynaertii.
AID243774	Percent inhibition of alpha-galactosidase of Aspergillus niger at 1000 uM	2005	Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6	Biological properties of D- and L-1-deoxyazasugars.
AID514924	Inhibition of Bacteroides thetaiotaomicron GH92 alpha-mannosidase 2199 assessed as reduction of mannose release using 4NP-mannopyranoside substrate	2010	Nature chemical biology, Feb, Volume: 6, Issue:2	Mechanistic insights into a Ca2+-dependent family of alpha-mannosidases in a human gut symbiont.
AID238243	Ki value against bovine alpha-L-fucosidase	2005	Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6	Biological properties of D- and L-1-deoxyazasugars.
AID243724	Percent inhibition of alpha-galactosidase of coffee bean at 1000 uM	2005	Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6	Biological properties of D- and L-1-deoxyazasugars.
AID243746	Percent inhibition of beta-galactosidase of rat epididymis at 1000 uM	2005	Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6	Biological properties of D- and L-1-deoxyazasugars.
AID243658	Percent inhibition of human beta-galactosidase at 1000 uM	2005	Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6	Biological properties of D- and L-1-deoxyazasugars.
AID241119	Inhibitory concentration against alpha-mannosidase of jack bean	2005	Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6	Biological properties of D- and L-1-deoxyazasugars.
AID263087	Inhibition of jack beans alpha-mannosidase	2006	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 16, Issue:8	Fluorescent glycosidase inhibiting 1,5-dideoxy-1,5-iminoalditols.
AID648438	Inhibition of PMA-induced JAK1 phosphorylation in human PBMC at 90 uM after 15 mins by Western blot analysis	2012	Bioorganic & medicinal chemistry letters, Jan-01, Volume: 22, Issue:1	An iminosugar N-pentafluorobenzyl-1-deoxynojirimycin as a novel potential immunosuppressant for the treatment of Th2-related diseases.
AID648441	Inhibition of PMA-induced GATA3 expression in human PBMC at 90 uM after 15 mins by Western blot analysis	2012	Bioorganic & medicinal chemistry letters, Jan-01, Volume: 22, Issue:1	An iminosugar N-pentafluorobenzyl-1-deoxynojirimycin as a novel potential immunosuppressant for the treatment of Th2-related diseases.
AID497872	Inhibition of wild type Bacteroides thetaiotaomicron beta-mannosidase 2A expressed in Escherichia coli BL21 (DE3) at 37 degC and Ph 5.6 by 2,4-dinitrophenolate release assay	2008	Nature chemical biology, May, Volume: 4, Issue:5	Structural and biochemical evidence for a boat-like transition state in beta-mannosidases.
AID648436	Inhibition of ConA-induced phospho-JAK1 expression in human PBMC at 90 uM after 72 hrs by flow cytometry	2012	Bioorganic & medicinal chemistry letters, Jan-01, Volume: 22, Issue:1	An iminosugar N-pentafluorobenzyl-1-deoxynojirimycin as a novel potential immunosuppressant for the treatment of Th2-related diseases.
AID243640	Percent inhibition of human beta-mannosidase at 1000 uM	2005	Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6	Biological properties of D- and L-1-deoxyazasugars.
AID514932	Inhibition of Bacteroides thetaiotaomicron GH92 alpha-mannosidase 3990 assessed as reduction of mannose release using 4NP-mannopyranoside substrate	2010	Nature chemical biology, Feb, Volume: 6, Issue:2	Mechanistic insights into a Ca2+-dependent family of alpha-mannosidases in a human gut symbiont.
AID241268	Inhibitory concentration against alpha-mannosidase of rat epididymis	2005	Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6	Biological properties of D- and L-1-deoxyazasugars.
AID243651	Percent inhibition of human alpha-mannosidase at 1000 uM	2005	Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6	Biological properties of D- and L-1-deoxyazasugars.
AID648440	Inhibition of PMA-induced JAK1 expression in human PBMC at 90 uM after 15 mins by Western blot analysis	2012	Bioorganic & medicinal chemistry letters, Jan-01, Volume: 22, Issue:1	An iminosugar N-pentafluorobenzyl-1-deoxynojirimycin as a novel potential immunosuppressant for the treatment of Th2-related diseases.
AID977608	Experimentally measured binding affinity data (IC50) for protein-ligand complexes derived from PDB	2001	The EMBO journal, Jun-15, Volume: 20, Issue:12	Structure of Golgi alpha-mannosidase II: a target for inhibition of growth and metastasis of cancer cells.
AID1811	Experimentally measured binding affinity data derived from PDB	2001	The EMBO journal, Jun-15, Volume: 20, Issue:12	Structure of Golgi alpha-mannosidase II: a target for inhibition of growth and metastasis of cancer cells.
AID588519	A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities	2011	Antiviral research, Sep, Volume: 91, Issue:3	High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID1799390	Btman2A from Article 10.1038/nchembio.81: \\Structural and biochemical evidence for a boat-like transition state in beta-mannosidases.\\	2008	Nature chemical biology, May, Volume: 4, Issue:5	Structural and biochemical evidence for a boat-like transition state in beta-mannosidases.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	2 (18.18)	18.2507
2000's	5 (45.45)	29.6817
2010's	3 (27.27)	24.3611
2020's	1 (9.09)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	0 (0.00%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	11 (100.00%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes	Roles
1-deoxynojirimycin 1-deoxy-nojirimycin: structure in first source. duvoglustat : An optically active form of 2-(hydroxymethyl)piperidine-3,4,5-triol having 2R,3R,4R,5S-configuration.	2.95	4	2-(hydroxymethyl)piperidine-3,4,5-triol; piperidine alkaloid	anti-HIV agent; anti-obesity agent; bacterial metabolite; EC 3.2.1.20 (alpha-glucosidase) inhibitor; hepatoprotective agent; hypoglycemic agent; plant metabolite
miglustat miglustat: a glucosylceramide synthase inhibitor. miglustat : A hydroxypiperidine that is deoxynojirimycin in which the amino hydrogen is replaced by a butyl group.	2.04	1	piperidines; tertiary amino compound	anti-HIV agent; EC 2.4.1.80 (ceramide glucosyltransferase) inhibitor
swainsonine Swainsonine: An indolizidine alkaloid from the plant Swainsona canescens that is a potent alpha-mannosidase inhibitor. Swainsonine also exhibits antimetastatic, antiproliferative, and immunomodulatory activity.. swainsonine : An indolizidine alkaloid isolated from the plant Swainsona canescens with three hydroxy substituents at positions 1, 2 and 8.	2.7	3	indolizidine alkaloid	antineoplastic agent; EC 3.2.1.114 (mannosyl-oligosaccharide 1,3-1,6-alpha-mannosidase) inhibitor; immunological adjuvant; plant metabolite
castanospermine castanospermine: indolizidine alkaloid from seeds of Australian legume, Castanospermum australe. castanospermine : A tetrahydroxyindolizidine alkaloid that consists of octahydroindolizine having four hydroxy substituents located at positions 1, 6, 7 and 8 (the 1S,6S,7R,8R,8aR-diastereomer).	2.04	1	indolizidine alkaloid	anti-HIV-1 agent; anti-inflammatory agent; EC 3.2.1.* (glycosidase) inhibitor; metabolite
2-acetamido-1,5-imino-1,2,5-trideoxy-d-glucitol 2-acetamido-1,5-imino-1,2,5-trideoxy-D-glucitol: structure given in first source	2.03	1
deoxyfuconojirimycin deoxyfuconojirimycin: structure given in first source. deoxyfuconojirimycin : A hydroxypiperidine in which the three hydroxy substituents are located at positions 3, 4 and 5 together with an additional methyl substituent at position 2.	2.71	3	hydroxypiperidine; triol	fungal metabolite
1,2,3,4-tetrahydroxy-nor-tropane calystegine B(2): RN given for (2-endo,3-exo,4-endo)-isomer; structure in first source	2.04	1
2,5-dihydroxymethyl-3,4-dihydroxypyrrolidine 2,5-dihydroxymethyl-3,4-dihydroxypyrrolidine: structure given in first source	1.98	1	dihydroxypyrrolidine
kifunensine kifunensine: inhibitor of the glycoprotein processing mannosidase I; from actinomycete Kitasatosporia kifunense 9482; structure given in first source; RN given refers to (5R-(5alpha,6beta,7alpha,8alpha,8aalpha))-isomer; RN for cpd without isomeric designation not avail 10/90	2.43	2
homonojirimycin homonojirimycin: inhibits alpha-glucosidase; RN given for (2R-(2alpha,3alpha,4beta,5alpha,6beta))-isomer; structure in first source	1.99	1
migalastat migalastat: a potent inhibitor of glycolipid biosynthesis	2.43	2	piperidines
isofagomine [no description available]	2.44	2	piperidines
4-nitrophenyl-alpha-d-mannopyranoside 4-nitrophenyl-alpha-D-mannopyranoside: see also record for (beta)-isomer	2.05	1
1,4-dideoxy-1,4-imino-d-arabinitol [no description available]	1.98	1
cyclosporine ramihyphin A: one of the metabolites produced by Fusarium sp. S-435; RN given refers to cpd with unknown MF	2.07	1	homodetic cyclic peptide	anti-asthmatic drug; anticoronaviral agent; antifungal agent; antirheumatic drug; carcinogenic agent; dermatologic drug; EC 3.1.3.16 (phosphoprotein phosphatase) inhibitor; geroprotector; immunosuppressive agent; metabolite
l-altro-1-deoxynojirimycin L-altro-1-deoxynojirimycin: structure in first source	2.02	1

Condition	Relationship Strength	Studies
Metastase [description not available]	2	1
Neoplasm Metastasis The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.	2	1
Encephalitis, Polio [description not available]	2.06	1
Poliomyelitis An acute infectious disease of humans, particularly children, caused by any of three serotypes of human poliovirus (POLIOVIRUS). Usually the infection is limited to the gastrointestinal tract and nasopharynx, and is often asymptomatic. The central nervous system, primarily the spinal cord, may be affected, leading to rapidly progressive paralysis, coarse FASCICULATION and hyporeflexia. Motor neurons are primarily affected. Encephalitis may also occur. The virus replicates in the nervous system, and may cause significant neuronal loss, most notably in the spinal cord. A rare related condition, nonpoliovirus poliomyelitis, may result from infections with nonpoliovirus enteroviruses. (From Adams et al., Principles of Neurology, 6th ed, pp764-5)	2.06	1
Bilharziasis [description not available]	2.07	1
Schistosomiasis Infection with flukes (trematodes) of the genus SCHISTOSOMA. Three species produce the most frequent clinical diseases: SCHISTOSOMA HAEMATOBIUM (endemic in Africa and the Middle East), SCHISTOSOMA MANSONI (in Egypt, northern and southern Africa, some West Indies islands, northern 2/3 of South America), and SCHISTOSOMA JAPONICUM (in Japan, China, the Philippines, Celebes, Thailand, Laos). S. mansoni is often seen in Puerto Ricans living in the United States.	2.07	1

1-deoxymannojirimycin

Cross-References

Synonyms (34)

Protein Targets (36)

Potency Measurements

Inhibition Measurements

Biological Processes (25)

Molecular Functions (9)

Ceullar Components (10)

Bioassays (41)

Research

Studies (11)

Market Indicators

Research Demand Index: 28.76

Study Types

1-deoxymannojirimycin

Cross-References

Synonyms (34)

Protein Targets (36)

Potency Measurements

Inhibition Measurements

Biological Processes (25)

Molecular Functions (9)

Ceullar Components (10)

Bioassays (41)

Research

Studies (11)

Market Indicators

Research Demand Index: 28.76

Study Types

Related Drugs (16)

Related Conditions (6)